dr. christina baik on alectinib versus crizotinib in alk-positive lung cancer
Published 8 years ago • 574 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
1:12
dr. christina baik on alectinib in patients with alk-lung cancer
-
1:06
comparing alectinib versus crizotinib in alk nsclc
-
3:04
phase iii results for alectinib compared with crizotinib in alk metastatic nsclc
-
4:00
alectinib eclipses crizotnib for alk positive lung cancer
-
1:52
dr. shaw on crizotinib versus chemotherapy in alk-positive nsclc
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
1:58
dr. shaw on crizotinib in alk-positive lung cancer
-
6:51
progression in alk nsclc after frontline therapy
-
1:21
dr. shaw on crizotinib resistance in alk-positive lung cancer
-
0:41
dr. gandhi discusses the role of alectinib in alk lung cancer
-
1:07
dr. massarelli on first-line alk nsclc treatment
-
1:22
assessing the efficacy of alectinib versus crizotinib in alk-positive nsclc
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
0:44
dr. mark kris discusses crizotinib for patients with alk-positive lung cancer
-
2:18
dr. maurie markman on the profile 1007 crizotinib trial
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
3:59
alectinib in alk-mutated nsclc
-
1:52
dr. drilon on the utility of brigatinib in alk nsclc
-
3:44
alk inhibitors for acquired resistance: zykadia and alectinib